Novartis (NVS) announced promising results from its Phase 3 APPLAUSE IgAN study, demonstrating that its drug Fabhalta (iptacopan) significantly slowed kidney function decline by 49.3% compared to placebo in patients with IgA nephropathy. These findings, published in the New England Journal of Medicine, highlight Fabhalta’s potential to address a critical unmet need in treating this chronic autoimmune kidney disease, which often leads to severe complications like dialysis or transplant.
The study’s results indicate not only a reduced decline in estimated glomerular filtration rate (eGFR) but also a 43% lower risk of reaching kidney failure events among Fabhalta-treated patients. With the drug already receiving accelerated approval in the U.S. and China, Novartis has submitted the complete two-year data for traditional FDA approval, which has been granted priority review. This positions Novartis favorably in the market for chronic kidney disease treatments.
For investors, the successful outcomes of this study could bolster Novartis’s stock performance, especially as the company expands its portfolio in the kidney disease space. The stock’s current trading range suggests potential for growth as regulatory milestones are approached.
Source: nasdaq.com